JP2008543781A - ホスフオジエステラーゼ４阻害剤 - Google Patents

ホスフオジエステラーゼ４阻害剤 Download PDF

Info

Publication number
JP2008543781A
JP2008543781A JP2008515998A JP2008515998A JP2008543781A JP 2008543781 A JP2008543781 A JP 2008543781A JP 2008515998 A JP2008515998 A JP 2008515998A JP 2008515998 A JP2008515998 A JP 2008515998A JP 2008543781 A JP2008543781 A JP 2008543781A
Authority
JP
Japan
Prior art keywords
alkyl
substituted
unsubstituted
halogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008515998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543781A5 (enExample
Inventor
ザビエル タラマス，フランシスコ
マリー カルーン，ジョアン
ダン，ロバート
ホッパー，アレン
キュエスター，エリック
シューマッハー，リチャード
テヒム，アショック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of JP2008543781A publication Critical patent/JP2008543781A/ja
Publication of JP2008543781A5 publication Critical patent/JP2008543781A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
JP2008515998A 2005-06-10 2006-06-09 ホスフオジエステラーゼ４阻害剤 Pending JP2008543781A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68906005P 2005-06-10 2005-06-10
PCT/US2006/022655 WO2006135828A2 (en) 2005-06-10 2006-06-09 Trisubstituted amines as phosphodiesterase 4 inhibitors

Publications (2)

Publication Number Publication Date
JP2008543781A true JP2008543781A (ja) 2008-12-04
JP2008543781A5 JP2008543781A5 (enExample) 2009-07-02

Family

ID=37075617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008515998A Pending JP2008543781A (ja) 2005-06-10 2006-06-09 ホスフオジエステラーゼ４阻害剤

Country Status (6)

Country Link
US (2) US20070049611A1 (enExample)
EP (1) EP1888528A2 (enExample)
JP (1) JP2008543781A (enExample)
AU (1) AU2006257863A1 (enExample)
CA (1) CA2611562A1 (enExample)
WO (1) WO2006135828A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008137997A (ja) * 2006-11-10 2008-06-19 Otsuka Pharmaceut Co Ltd 医薬
JP2010513334A (ja) * 2006-12-22 2010-04-30 レオ ファーマ アクティーゼルスカブ Ｐｄｅ４阻害剤として有用な置換アセトフェノン
JP2011517687A (ja) * 2008-04-14 2011-06-16 シエシー ファルマセウティチィ ソシエタ ペル アチオニ ホスホジエステラーゼ−４阻害剤としての第３アミン誘導体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363565T3 (es) * 2006-12-22 2011-08-09 Leo Pharma A/S Acetofenonas sustituidas útiles como inhibidores de pde4.
ES2544482T3 (es) * 2007-02-27 2015-08-31 National University Corporation Okayama University Compuesto rexinoide que tiene un grupo alcoxi
FR2915098B1 (fr) * 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
FR2915100B1 (fr) * 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
FR2915099B1 (fr) * 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
JP5542059B2 (ja) * 2008-10-09 2014-07-09 国立大学法人 岡山大学 Ｒｘｒ作動性物質を有効成分とする抗アレルギー剤
WO2010059372A2 (en) * 2008-10-30 2010-05-27 Herbalscience Group, Llc Tryptase enzyme inhibiting aminopyridines
WO2010053902A2 (en) * 2008-11-04 2010-05-14 Herbalscience Group, Llc Tryptase enzyme inhibiting aminothiophenols
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AU2012337781B2 (en) 2011-11-15 2017-07-06 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
AU2014307802A1 (en) * 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with combination therapy
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
US20170119775A1 (en) * 2014-03-28 2017-05-04 Algiax Pharmaceuticals Gmbh Treatment of cognitive disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509654A (ja) * 1994-01-26 1997-09-30 ローン−プーラン・ロレ・リミテツド サイクリックａｍｐホスホジエステラーゼおよびｔｎｆ阻害剤としての置換芳香族化合物
JPH1072415A (ja) * 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
WO2002074726A2 (en) * 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2004009552A1 (en) * 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
WO2004046113A2 (en) * 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2244520B1 (enExample) * 1973-07-06 1977-02-04 Ugine Kuhlmann
US4524373A (en) * 1982-02-24 1985-06-18 Kanzaki Paper Manufacturing Co., Ltd. Fluoran derivatives as new compounds, process for preparing the same and recording system utilizing the same as colorless chromogenic material
US5204226A (en) * 1991-03-04 1993-04-20 International Business Machines Corporation Photosensitizers for polysilanes
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO1998058901A1 (en) * 1997-06-24 1998-12-30 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivates
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2002258400A1 (en) * 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US6986126B2 (en) * 2001-04-13 2006-01-10 Sun Microsystems, Inc. Method and apparatus for detecting violations of type rules in a computer program
US20030149052A1 (en) * 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509654A (ja) * 1994-01-26 1997-09-30 ローン−プーラン・ロレ・リミテツド サイクリックａｍｐホスホジエステラーゼおよびｔｎｆ阻害剤としての置換芳香族化合物
JPH1072415A (ja) * 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
WO2002074726A2 (en) * 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2004009552A1 (en) * 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
WO2004046113A2 (en) * 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN7012002074; ＳＴＮ　ＯＮ　ＴＨＥ　ＷＥＢ，　ＦＩＬＥ　ＣＡＰＬＵＳ，　ＡＣＣＥＳＳＩＯＮ　ＮＯ．１９７３：１５９３７９，　ＲＮ＝４１２９３-０８-７，４１２９３-０９-８，４１２９３-１０-１，４１２９３-１４- *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008137997A (ja) * 2006-11-10 2008-06-19 Otsuka Pharmaceut Co Ltd 医薬
JP2010513334A (ja) * 2006-12-22 2010-04-30 レオ ファーマ アクティーゼルスカブ Ｐｄｅ４阻害剤として有用な置換アセトフェノン
JP2011517687A (ja) * 2008-04-14 2011-06-16 シエシー ファルマセウティチィ ソシエタ ペル アチオニ ホスホジエステラーゼ−４阻害剤としての第３アミン誘導体

Also Published As

Publication number Publication date
AU2006257863A1 (en) 2006-12-21
US20070049611A1 (en) 2007-03-01
CA2611562A1 (en) 2006-12-21
EP1888528A2 (en) 2008-02-20
WO2006135828A3 (en) 2007-04-26
WO2006135828A2 (en) 2006-12-21
US20090118270A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
US20090118270A1 (en) Phosphodiesterase 4 inhibitors
JP2007513957A (ja) Ｎ−置換ジアリールアミン類縁体を含む，ホスホジエステラーゼ４阻害剤本出願は，参照によりその全開示がここに導入されている２００３年１２月１１日に提出した米国仮出願番号６０／５２８，４８６の利益を請求するものである。
JP5094398B2 (ja) 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用
CN106659914B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
KR102438302B1 (ko) 리신 특이적 데메틸라제-1의 억제제
CN100513397C (zh) 磷酸二酯酶4抑制剂
US20100168167A1 (en) Piperidinones Useful in the Treatment of Inflammation
TWI797111B (zh) 雙重magl及faah抑制劑
JP2008513505A5 (enExample)
JP2006504656A (ja) Ｎ−置換されたアニリン及びジフェニルアミンアナログを含むホスホジエステラーゼ４インヒビター
HRP20030662A2 (en) Phosphodiesterase 4 inhibitors
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
RU2354648C2 (ru) Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
US7153871B2 (en) Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US20240059677A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
WO2022132803A1 (en) Cb2 receptor agonists
HK1081194B (en) 6-amino-1h-indazole compounds as phosphodiesterase 4 inhibitors, pharmaceutical compositions comprising the same, and use thereof
NZ547469A (en) 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130305